Abstract
Gadolinium (Gd) enhancement of multiple sclerosis (MS) lesions on MRI scans is a commonly used outcome measure in therapeutic trials. However, enhancement depends on MRI acquisition parameters that might significantly alter detectability. We investigated how the difference in blood–brain barrier (BBB) permeability threshold between MRI protocols affects lesion detection and apparent enhancement time using dynamic-contrast-enhanced (DCE) MRI. We examined fourty-four relapsing-remitting MS patients with two MRI protocols: ‘standard sensitivity’ (SS) (1.5 T, single-dose Gd) and ‘high sensitivity’ (HS) (3 T, triple-dose Gd, delayed acquisition). Eleven patients had at least one enhancing lesion and completed the 1-month follow-up. We acquired DCE-MRI during the HS protocol and calculated BBB permeability. Sixty-five lesions were enhanced with the SS vs. 135 with the HS protocol. The detection threshold of the HS was significantly lower than that of the SS protocol (K trans = 2.64 vs. 4.00E−3 min−1, p < 0.01). Most lesions (74 %) were in the recovery phase; none were in the onset phase and 26 % were at the peak of enhancement. The estimated duration of detectability with the HS protocol was significantly longer than for the SS protocol (6–12 weeks vs. 3 weeks). Our observations on the protocol-dependent threshold for detection and time-course help explain discrepancies in the observed effects of anti-inflammatory therapies on MS lesions.
Similar content being viewed by others
References
Barkhof F, Held U, Simon JH, Daumer M, Fazekas F, Filippi M, Frank JA, Kappos L, Li D, Menzler S, Miller DH, Petkau J, Wolinsky J, for the Sylvia Lawry Centre for MSR (2005) Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. Neurology 65:1447–1454
Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD (2009) Efficacy of treatment of MS with IFNβ-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 72:1976–1983
Cotton F, Weiner H, Jolesz F, Guttmann C (2003) MRI contrast uptake in new lesions in relapsing–remitting MS followed at weekly intervals. Neurology 60:640–646
Deoni SC, Rutt BK, Peters TM (2003) Rapid combined T1 and T2 mapping using gradient recalled acquisition in the steady state. Magn Reson Med 49:515–526
Dhib-Jalbut S (2002) Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 58:S3–S9
Durelli L, Clerico M (2005) Comparison of immunomodulatory treatments for multiple sclerosis. Eur J Neurol Off J Eur Fed Neurol Soc 12:915
Erskine MK, Cook LL, Riddle KE, Mitchell JR, Karlik SJ (2005) Resolution-dependent estimates of multiple sclerosis lesion loads. Can J Neurol Sci 32:205–212
Filippi M, Mastronardo G, Bastianello S, Rocca MA, Rovaris M, Gasperini C, Pozzilli C, Comi G (1998) A longitudinal brain MRI study comparing the sensitivities of the conventional and a newer approach for detecting active lesions in multiple sclerosis. J Neurol Sci 159:94–101
Filippi M, Rovaris M, Capra R, Gasperini C, Yousry TA, Sormani MP, Prandini F, Horsfield MA, Martinelli V, Bastianello S, Kühne I, Pozzilli C, Comi G (1998) A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain 121:2011–2020
Footit C, Cron GO, Nguyen TV, Cameron I, Schweitzer ME, Sinclair J, Woulfe J, Hogan MJ, Nguyen TB (2011) Optimizing perfusion imaging of brain tumors: Validation of venous output function used as a surrogate AIF. In: 19th Proceedings of the international society for magnetic resonance in medicine. Abstract #2038
Francis G (2004) Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS. J Neurol 251(Suppl):5
Gay D, Esiri M (1991) Blood–brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. Brain J Neurol 114(Pt 1B):557–572
Giovannoni G, Silver NC, Good CD, Miller DH, Thompson EJ (2000) Immunological time-course of gadolinium-enhancing MRI lesions in patients with multiple sclerosis. Eur Neurol 44:222–228
Ingrisch M, Sourbron S, Morhard D, Ertl-Wagner B, Kümpfel T, Hohlfeld R, Reiser M, Glaser C (2012) Quantification of perfusion and permeability in multiple sclerosis: dynamic contrast-enhanced MRI in 3D at 3 T. Invest Radiol 47:252–258
Jelescu IO, Leppert IR, Narayanan S, Araújo D, Arnold DL, Pike GB (2011) Dual-temporal resolution dynamic contrast-enhanced MRI protocol for blood–brain barrier permeability measurement in enhancing multiple sclerosis lesions. J Magn Reson Imaging 33:1291–1300
Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, Miller D, Guttmann CR, Weiner HL, Gasperini C, Filippi M (1999) Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI meta-analysis group. Lancet 353:964–969
Lavini C, Verhoeff J (2010) Reproducibility of the gadolinium concentration measurements and of the fitting parameters of the vascular input function in the superior sagittal sinus in a patient population. Magn Reson Imaging
Livshits I, Hussein S, Kennedy C, Weinstock-Guttman B, Hojnacki D, Zivadinov R (2012) Comparison of a 1.5 T standard vs. 3 T optimized protocols in multiple sclerosis patients. Minerva Med 103:97–102
Mikol D, Barkhof F, Chang P, Coyle P, Jeffery D, Schwid S, Stubinski B, Uitdehaag B (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs glatiramer acetate in relapsing MS disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7:903–914
O’Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung H-P, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T (2009) 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing–remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8:889–897
Petkau J, Reingold SC, Held U, Cutter GR, Fleming TR, Hughes MD, Miller DH, McFarland HF, Wolinsky JS (2008) Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Mult Scler 14:770–778
Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann H-J (2005) Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 40:715–724
Sicotte NL, Voskuhl RR, Bouvier S, Klutch R, Cohen MS, Mazziotta JC (2003) Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla. Invest Radiol 38:423–427
Silver NC, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, McDonald WI, Miller DH (1997) Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 120:1149–1161
Silver NC, Good CD, Sormani MP, MacManus DG, Thompson AJ, Filippi M, Miller DH (2001) A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis. J Neurol 248:215–224
Sormani M, Bonzano L, Roccatagliata L, Cutter G, Mancardi G, Bruzzi P (2009) Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 65:268–275
Sormani MP, Li DK, Bruzzi P, Stubinski B, Cornelisse P, Rocak S, De Stefano N (2011) Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology 77:1684–1690
Tofts PS (1996) Optimal detection of blood-brain barrier defects with Gd-DTPA MRI—the influences of delayed imaging and optimised repetition time. Magn Reson Imaging 14:373–380
Tofts PS, Kermode AG (1991) Measurement of the blood–brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17:357–367
Wattjes M, Lutterbey G, Harzheim M, Gieseke J, Träber F, Klotz L, Klockgether T, Schild H (2006) Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5 T with 3.0 T. Eur Radiol 16:2067–2073
Wolansky LJ, Bardini JA, Cook SD, Zimmer AE, Sheffet A, Lee HJ (1994) Triple-dose versus single dose gadoteridol in multiple sclerosis patients. J Neuroimaging 4:141–145
Wu Y-Y, Wu C-H, Chiang C-M, Chen C-C, Chai J-W (2012) Consistency of permeability measurement using arterial input function and venous output function in DCE-MRI for metastatic brain tumors. In: 20th Proceedings of the international society for magnetic resonance in medicine. Abstract #3508
Yong W (2002) Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 59:802–808
Acknowledgments
We would like to thank Rozalia Arnaoutelis for her invaluable help in patient recruitment and booking. This work was supported by the Multiple Sclerosis Society of Canada.
Conflicts of interest
Dr. Arnold has served on advisory boards, received speaker honoraria, served as a consultant or received research support from Bayer, Biogen Idec, Coronado Biosciences, Consortium of Multiple Sclerosis Centers, Eli Lilly, EMD Serono, Genentech, Genzyme, GlaxoSmithKline, MS Forum, NeuroRx Research, Novartis, Opexa Therapeutics, Roche, Merck Serono, S.A., Serono Symposia International Foundation, Teva, the Canadian Institutes of Health Research, and the Multiple Sclerosis Society of Canada; and holds stock in NeuroRx Research. Dr. Narayanan has received personal compensation from NeuroRx Research, Teva Neurosciences Canada and Biogen Idec Canada for consulting services. Dr. Giacomini has received personal compensation from NeuroRx Research, Allergan, Bayer, Biogen Idec, Genzyme, Novartis, EMD Serono and Teva Neuroscience for speaking, advisory board participation or consulting services.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Leppert, I.R., Narayanan, S., Araújo, D. et al. Interpreting therapeutic effect in multiple sclerosis via MRI contrast enhancing lesions: now you see them, now you don’t. J Neurol 261, 809–816 (2014). https://doi.org/10.1007/s00415-014-7284-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-014-7284-0